No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Medicare Levy Change: 1.2 Million Aussies to Get Extra Tax Boost
When Can ASX 200 Investors Expect RBA Interest Rate Cuts?
Bulls Detective | With COVID-19 Vaccine Revenue Nearly Doubling, How Should Pfizer Respond to the Post-Pandemic Era?
Since the 2020 fuse, Pfizer has risen more than 96%. FY2021 revenue reached a record high of US$81.29 billion, up 94% year over year. The COVID-19 vaccine Comirnaty alone contributed 37 billion US dollars in revenue. How should Pfizer, which has earned a lot of cash, cope with the development of the post-pandemic epidemic?